Fig. 4
BMSC expansion of Gr-1LowCD11b+ is mediated by M-CSF. Twenty-four hours after BMSC treatment in BLM-treated mice, sera were collected from BLM and BMSC-treated mice (six mice from each group). a The relative expression levels of 40 mouse soluble proteins in the sera of BLM- and BMSC-treated mice were measured in duplicate using a Mouse Cytokine Array. The results shown are normalized to reference spots. b The concentration of M-CSF in serum collected from sham-, BLM-, and BMSC-treated mice (six mice from each group) was measured with ELISA in triplicate. Data presented are representative of two replicated experiments. *P < 0.01 as compared with the BLM group; #P < 0.01 as compared with the sham group. c C57BL/6 mice were treated with 5 mg/kg BLM in 30 μL normal saline via intratracheal instillation. BMSC (1 × 106/mouse) were administered via the tail vein 24 h after BLM treatment. On day 0, 2, 4, and 6 after BMSC administration, these mice were treated with 10 μg of anti-M-CSF mAb or isotype mAb i.p.. Lung specimens (six lungs from each group) were collected and the variations of Gr-1HighCD11b+/Gr-1LowCD11b+ were analyzed. *P < 0.01 as compared with the BMSC and the BMSC+Isotype mAb group. BLM bleomycin, BMSC bone marrow mesenchymal stem cells